- Home
- JELD vs BCAX Comparison
JELD vs BCAX Comparison
Compare JELD & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JELD
- BCAX
- Stock Information
- Founded
- JELD 1960
- BCAX 2018
- Country
- JELD United States
- BCAX United States
- Employees
- JELD 17700
- BCAX N/A
- Industry
- JELD Forest Products
- BCAX
- Sector
- JELD Basic Materials
- BCAX
- Exchange
- JELD Nasdaq
- BCAX NYSE
- Market Cap
- JELD 707.4M
- BCAX 1.0B
- IPO Year
- JELD 2017
- BCAX 2024
- Fundamental
- Price
- JELD $8.36
- BCAX $19.12
- Analyst Decision
- JELD Hold
- BCAX Strong Buy
- Analyst Count
- JELD 9
- BCAX 5
- Target Price
- JELD $13.63
- BCAX $41.33
- AVG Volume (30 Days)
- JELD 609.2K
- BCAX 574.3K
- Earning Date
- JELD 02-18-2025
- BCAX 02-16-2025
- Dividend Yield
- JELD N/A
- BCAX N/A
- EPS Growth
- JELD N/A
- BCAX N/A
- EPS
- JELD N/A
- BCAX N/A
- Revenue
- JELD $3,900,923,000.00
- BCAX N/A
- Revenue This Year
- JELD N/A
- BCAX N/A
- Revenue Next Year
- JELD N/A
- BCAX N/A
- P/E Ratio
- JELD N/A
- BCAX N/A
- Revenue Growth
- JELD N/A
- BCAX N/A
- 52 Week Low
- JELD $8.15
- BCAX $16.01
- 52 Week High
- JELD $21.75
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- JELD 21.98
- BCAX N/A
- Support Level
- JELD $8.30
- BCAX N/A
- Resistance Level
- JELD $10.79
- BCAX N/A
- Average True Range (ATR)
- JELD 0.40
- BCAX 0.00
- MACD
- JELD -0.16
- BCAX 0.00
- Stochastic Oscillator
- JELD 7.45
- BCAX 0.00
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.